[{"id":"02bd8df0-2fe4-44b2-8867-3c5d0ec54fff","acronym":"","url":"https://clinicaltrials.gov/study/NCT03888092","created_at":"2021-01-18T19:09:24.084Z","updated_at":"2024-07-02T16:35:52.781Z","phase":"Phase 1/2","brief_title":"Z650 in Advanced Esophageal Squamous Cell Carcinoma With EGFR Over Expression or Gene Amplification","source_id_and_acronym":"NCT03888092","lead_sponsor":"Sunshine Lake Pharma Co., Ltd.","biomarkers":" EGFR","pipe":" | ","alterations":" EGFR overexpression","tags":["EGFR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR overexpression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e larotinib (Z650)"],"overall_status":"Completed","enrollment":" Enrollment 81","initiation":"Initiation: 08/18/2017","start_date":" 08/18/2017","primary_txt":" Primary completion: 12/13/2022","primary_completion_date":" 12/13/2022","study_txt":" Completion: 12/13/2022","study_completion_date":" 12/13/2022","last_update_posted":"2023-03-21"},{"id":"9653dfea-b314-42ba-85bf-254d9e1c24d8","acronym":"","url":"https://clinicaltrials.gov/study/NCT04415853","created_at":"2021-01-18T21:17:00.808Z","updated_at":"2024-07-02T16:36:05.477Z","phase":"Phase 3","brief_title":"Study of Larotinib in Unresectable Advanced or Recurrent Esophageal Cancer","source_id_and_acronym":"NCT04415853","lead_sponsor":"Sunshine Lake Pharma Co., Ltd.","biomarkers":" EGFR","pipe":" | ","alterations":" EGFR expression • EGFR overexpression","tags":["EGFR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR expression • EGFR overexpression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e irinotecan • Teysuno (gimeracil/oteracil/tegafur) • larotinib (Z650)"],"overall_status":"Recruiting","enrollment":" Enrollment 416","initiation":"Initiation: 01/21/2021","start_date":" 01/21/2021","primary_txt":" Primary completion: 08/01/2023","primary_completion_date":" 08/01/2023","study_txt":" Completion: 11/01/2023","study_completion_date":" 11/01/2023","last_update_posted":"2022-08-15"}]